<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03608839</url>
  </required_header>
  <id_info>
    <org_study_id>003</org_study_id>
    <nct_id>NCT03608839</nct_id>
  </id_info>
  <brief_title>Effect of Dexamethasone on Reduction of Macular Thickness in Diabetic Patients, a Randomized Clinical Trial</brief_title>
  <acronym>EDRMT</acronym>
  <official_title>Effect of Dexamethasone on Reduction of Macular Thickness in Diabetic Patients, a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Federal de Pernambuco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade Federal de Pernambuco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: To determine the impact of short-term 4mg/ml dexamethasone solution treatment in
      diabetic macular edema (DME).

      Design: Phase II, randomized, prospective, parallel, interventional study.

      Participants: Pseudophakic patients with central-involved DME.

      Methods: Twenty-seven patients with visual impairment caused by DME were randomized in a
      1:1:1 ratio, in order to investigate treatment with 0.01 ml, 0.03 ml and 0.05 ml
      intravitreous dexamethasone solutions, and followed-up over 28 days

      Outcome Measures: The primary outcome was macular thickness at three days after intravitreous
      dexamethasone. The secondary outcomes were macular thickness at 28 days after intravitreous
      dexamethasone, best-corrected visual acuity (BCVA) and intraocular pressure (IOP) at three
      and 28 days after intravitreous dexamethasone
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, phase II, randomized, interventional, monocentric study. Data of
      consecutive patients with DME who volunteered to participate in the research at the
      department of ophthalmology of State University of Campinas (UNICAMP) - Brazil between May
      2016 and December 2017 were analysed.

      At the screening visit, all patients underwent complete ophthalmic evaluation, including best
      corrected visual acuity (BCVA), slit-lamp biomicroscopy, applanation tonometry, fundus
      biomicroscopy, fluorescein angiography (Visucam NM/ FA Carl Zeiss; Carl Zeiss Meditec,
      California, USA), SD- OCT (Spectralis; Heidelberg Engineering, Heidelberg, Germany). Central
      macular thickness was obtained through 7 horizontal lines ( 30° x 5° area), centered on the
      fovea, with 1536 A scans per line at 240 µm intervals.

      At the baseline study visit, patients were randomized with a 1:1:1 allocation to receive
      dexamethasone solution 4 mg/ml: 0,01 ml (40 µg) ; or 0,03 ml (120 µg); or 0,05 ml (200 µg).
      In follow up visits (1, 3, 7, 14, 21, 28 days after) were performed BCVA, slit-lamp
      biomicroscopy, applanation tonometry, fundus biomicroscopy, SD- OCT.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2016</start_date>
  <completion_date type="Actual">October 5, 2018</completion_date>
  <primary_completion_date type="Actual">December 20, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>At the baseline study visit, patients were randomized with a 1:1:1 allocation to receive dexamethasone solution 4 mg/ml: 0,01 ml (40 µg); or 0,03 ml (120 µg); or 0,05 ml (200 µg). In follow up visits (1, 3, 7, 14, 21, 28 days after) were performed BCVA, slit-lamp biomicroscopy, applanation tonometry, fundus biomicroscopy, SD- OCT (Spectralis; Heidelberg Engineering, Heidelberg, Germany). The randomization schedule was computer generated and stored in a locked cabinet until the study ended. Both patients and the study personnel who collected BCVA, OCT data were masked to the patient study assignment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>All the patients were masked. They didn't have acess to the group they belonged.
The care provider didn't know the quantity of the drug injected. The outcome assessor was masked as well.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Macular Thickness at 3 Days After Intravitreous Dexamethasone</measure>
    <time_frame>Three days after intravitreous dexamethasone</time_frame>
    <description>Measure macular thickness at 3 days after intravitreous dexamethasone with OCT - unit µm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Macular Thickness at 28 Days After Intravitreous Dexamethasone</measure>
    <time_frame>28 days after intravitreous dexamethasone</time_frame>
    <description>Measure macular thickness at 28 days after intravitreous dexamethasone with OCT - unit µm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity (BCVA) at 3 Days After Intravitreous Dexamethasone</measure>
    <time_frame>Three days after intravitreous dexamethasone</time_frame>
    <description>Measure best corrected visual acuity (BCVA) at 3 days after intravitreous dexamethasone with ETDRS chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity (BCVA) at 28 Days After Intravitreous Dexamethasone</measure>
    <time_frame>28 days after intravitreous dexamethasone</time_frame>
    <description>Measure best corrected visual acuity (BCVA) at 28 days after intravitreous dexamethasone with ETDRS chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular Pressure (IOP) at 3 Days After Intravitreous Dexamethasone</measure>
    <time_frame>3 days after intravitreous dexamethasone</time_frame>
    <description>Measure intraocular pressure (IOP) 3 days after intravitreous dexamethasone - unit mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular Pressure (IOP) at 28 Days After Intravitreous Dexamethasone</measure>
    <time_frame>28 days after intravitreous dexamethasone</time_frame>
    <description>Measure intraocular pressure (IOP) 28 days intravitreous dexamethasone - unit mmHg</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>0,01ml dexamethasone solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One intravitreous injection of 0,01 ml dexamethasone solution 4 mg/ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0,03 ml dexamethasone solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One intravitreous injection of 0,03 ml dexamethasone solution 4 mg/ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0,05 ml dexamethasone solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One intravitreous injection of 0,05 ml dexamethasone solution 4 mg/ml.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreous Dexamethasone Solution 4mg/ml - vol 0,01 ml</intervention_name>
    <description>0,01 ml intravitreous dexamethasone solution 4mg/ml injection.</description>
    <arm_group_label>0,01ml dexamethasone solution</arm_group_label>
    <other_name>0,01 ml intravitreous dexamethasone solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreous Dexamethasone Solution 4mg/ml - vol 0,03 ml</intervention_name>
    <description>0,03 ml intravitreous dexamethasone solution 4mg/ml injection.</description>
    <arm_group_label>0,03 ml dexamethasone solution</arm_group_label>
    <other_name>0,03 ml intravitreous dexamethasone solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreous Dexamethasone Solution 4mg/ml - vol 0,05 ml</intervention_name>
    <description>0,05 ml intravitreous dexamethasone solution 4mg/ml injection.</description>
    <arm_group_label>0,05 ml dexamethasone solution</arm_group_label>
    <other_name>0,05 ml intravitreous dexamethasone solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; = 18 years;

          -  diagnosis of DM type 2;

          -  pseudophakic patients

          -  presence of clinically significant DME according to ETDRS guidelines;

          -  best correct visual acuity (BCVA) between 20/400 and 20/40;

          -  central macular thickness (CMT) &gt;= 300 µm measured by spectral domain optical
             coherence tomography ( Spectralis® Heidelberg). If both eyes of the patient met the
             elegibility criteria, the eye with worse BCVA at baseline was designated as the study
             eye.

        Exclusion Criteria:

          -  any treatment of DME in the previous 4 months;

          -  pan retinal photocoagulation (PRP) in the previous 4 months or antecipated need of PRP
             for the next 6 months;

          -  any ophthalmologic surgery performed in the previous 4 months;

          -  history of pars plana vitrectomy;

          -  history of open-angle glaucoma or intraocular pressure elevation induced by
             corticosteroids that required anti-glaucomatous treatment or anti- hypertensive ocular
             treatment;

          -  intraocular pressure &gt;= 21 mmHg;

          -  patients with characteristics that meet the inclusion criteria, but refused to sign
             the written general consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodrigo PC Lira, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Campinas, Brazil</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>State University of Campinas</name>
      <address>
        <city>Campinas</city>
        <state>Sao Paulo</state>
        <zip>13083887</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Maturi RK, Glassman AR, Liu D, Beck RW, Bhavsar AR, Bressler NM, Jampol LM, Melia M, Punjabi OS, Salehi-Had H, Sun JK; Diabetic Retinopathy Clinical Research Network. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial. JAMA Ophthalmol. 2018 Jan 1;136(1):29-38. doi: 10.1001/jamaophthalmol.2017.4914.</citation>
    <PMID>29127949</PMID>
  </reference>
  <reference>
    <citation>Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL 3rd, Friedman SM, Glassman AR, Miller KM, Scott IU, Stockdale CR, Sun JK. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010 Jun;117(6):1064-1077.e35. doi: 10.1016/j.ophtha.2010.02.031. Epub 2010 Apr 28.</citation>
    <PMID>20427088</PMID>
  </reference>
  <reference>
    <citation>Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL 3rd, Friedman SM, Glassman AR, Scott IU, Stockdale CR, Sun JK; Diabetic Retinopathy Clinical Research Network. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011 Apr;118(4):609-14. doi: 10.1016/j.ophtha.2010.12.033.</citation>
    <PMID>21459214</PMID>
  </reference>
  <reference>
    <citation>Tamura H, Miyamoto K, Kiryu J, Miyahara S, Katsuta H, Hirose F, Musashi K, Yoshimura N. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci. 2005 Apr;46(4):1440-4.</citation>
    <PMID>15790913</PMID>
  </reference>
  <reference>
    <citation>Wang K, Wang Y, Gao L, Li X, Li M, Guo J. Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Biol Pharm Bull. 2008 Aug;31(8):1541-6.</citation>
    <PMID>18670086</PMID>
  </reference>
  <reference>
    <citation>Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, Sutter F, Simader C, Burian G, Gerstner O, Weichselberger A; RESTORE study group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011 Apr;118(4):615-25. doi: 10.1016/j.ophtha.2011.01.031.</citation>
    <PMID>21459215</PMID>
  </reference>
  <reference>
    <citation>Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, Rubio RG, Ehrlich JS; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012 Apr;119(4):789-801. doi: 10.1016/j.ophtha.2011.12.039. Epub 2012 Feb 11.</citation>
    <PMID>22330964</PMID>
  </reference>
  <reference>
    <citation>Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985 Dec;103(12):1796-806.</citation>
    <PMID>2866759</PMID>
  </reference>
  <reference>
    <citation>Bandello F, Battaglia Parodi M, Lanzetta P, Loewenstein A, Massin P, Menchini F, Veritti D. Diabetic macular edema. Dev Ophthalmol. 2010;47:73-110. doi: 10.1159/000320075. Epub 2010 Aug 10. Review.</citation>
    <PMID>20703045</PMID>
  </reference>
  <reference>
    <citation>Kempen JH, O'Colmain BJ, Leske MC, Haffner SM, Klein R, Moss SE, Taylor HR, Hamman RF; Eye Diseases Prevalence Research Group. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004 Apr;122(4):552-63.</citation>
    <PMID>15078674</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 12, 2018</study_first_submitted>
  <study_first_submitted_qc>July 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <results_first_submitted>October 12, 2018</results_first_submitted>
  <results_first_submitted_qc>October 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 8, 2019</results_first_posted>
  <last_update_submitted>October 5, 2019</last_update_submitted>
  <last_update_submitted_qc>October 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Federal de Pernambuco</investigator_affiliation>
    <investigator_full_name>Rodrigo Pessoa Cavalcanti Lira</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Diabetic macular edema</keyword>
  <keyword>Intravitreal dexamethasone solution</keyword>
  <keyword>Short term treament</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT03608839/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Data from DME diagnosed volunteers was collected and analyzed at the Department of Ophthalmology, State University of Campinas (UNICAMP), Brazil between May 2016 and December 2017</recruitment_details>
      <pre_assignment_details>Informed written consent was obtained from all patients, and approved by the ethics committee of the Clinical Hospital of the State University of Campinas</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>0,01ml Dexamethasone Solution</title>
          <description>One intravitreous injection of 0,01 ml dexamethasone solution 4 mg/ml.
Intravitreous Dexamethasone Solution 4mg/ml - vol 0,01 ml: 0,01 ml intravitreous dexamethasone solution 4mg/ml injection.</description>
        </group>
        <group group_id="P2">
          <title>0,03 ml Dexamethasone Solution</title>
          <description>One intravitreous injection of 0,03 ml dexamethasone solution 4 mg/ml.
Intravitreous Dexamethasone Solution 4mg/ml - vol 0,03 ml: 0,03 ml intravitreous dexamethasone solution 4mg/ml injection.</description>
        </group>
        <group group_id="P3">
          <title>0,05 ml Dexamethasone Solution</title>
          <description>One intravitreous injection of 0,05 ml dexamethasone solution 4 mg/ml.
Intravitreous Dexamethasone Solution 4mg/ml - vol 0,05 ml: 0,05 ml intravitreous dexamethasone solution 4mg/ml injection.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>0,01ml Dexamethasone Solution</title>
          <description>One intravitreous injection of 0,01 ml dexamethasone solution 4 mg/ml.
Intravitreous Dexamethasone Solution 4mg/ml - vol 0,01 ml: 0,01 ml intravitreous dexamethasone solution 4mg/ml injection.</description>
        </group>
        <group group_id="B2">
          <title>0,03 ml Dexamethasone Solution</title>
          <description>One intravitreous injection of 0,03 ml dexamethasone solution 4 mg/ml.
Intravitreous Dexamethasone Solution 4mg/ml - vol 0,03 ml: 0,03 ml intravitreous dexamethasone solution 4mg/ml injection.</description>
        </group>
        <group group_id="B3">
          <title>0,05 ml Dexamethasone Solution</title>
          <description>One intravitreous injection of 0,05 ml dexamethasone solution 4 mg/ml.
Intravitreous Dexamethasone Solution 4mg/ml - vol 0,05 ml: 0,05 ml intravitreous dexamethasone solution 4mg/ml injection.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" spread="5.63"/>
                    <measurement group_id="B2" value="65.5" spread="8.26"/>
                    <measurement group_id="B3" value="71.3" spread="7.36"/>
                    <measurement group_id="B4" value="67.9" spread="7.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eye (Right)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Epirretinal membrane</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Subretinal fluid</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Microaneurysms in foveal region</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Posterior vitreous detachment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Central macular thickness</title>
          <units>µm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="527.6" spread="154.21"/>
                    <measurement group_id="B2" value="630" spread="254.68"/>
                    <measurement group_id="B3" value="453.3" spread="140.39"/>
                    <measurement group_id="B4" value="537.4" spread="196.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Best corrected visual acuity</title>
          <units>ETDRS Letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.5" spread="13.98"/>
                    <measurement group_id="B2" value="47.2" spread="19.31"/>
                    <measurement group_id="B3" value="60" spread="15.31"/>
                    <measurement group_id="B4" value="53.2" spread="16.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intraocular pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.8" spread="2.02"/>
                    <measurement group_id="B2" value="13.22" spread="2.53"/>
                    <measurement group_id="B3" value="11.6" spread="2.55"/>
                    <measurement group_id="B4" value="12.2" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Macular Thickness at 3 Days After Intravitreous Dexamethasone</title>
        <description>Measure macular thickness at 3 days after intravitreous dexamethasone with OCT - unit µm</description>
        <time_frame>Three days after intravitreous dexamethasone</time_frame>
        <population>Macular thickness at 3 days after intravitreous dexamethasone</population>
        <group_list>
          <group group_id="O1">
            <title>0,01ml Dexamethasone Solution</title>
            <description>One intravitreous injection of 0,01 ml dexamethasone solution 4 mg/ml.
Intravitreous Dexamethasone Solution 4mg/ml - vol 0,01 ml: 0,01 ml intravitreous dexamethasone solution 4mg/ml injection.</description>
          </group>
          <group group_id="O2">
            <title>0,03 ml Dexamethasone Solution</title>
            <description>One intravitreous injection of 0,03 ml dexamethasone solution 4 mg/ml.
Intravitreous Dexamethasone Solution 4mg/ml - vol 0,03 ml: 0,03 ml intravitreous dexamethasone solution 4mg/ml injection.</description>
          </group>
          <group group_id="O3">
            <title>0,05 ml Dexamethasone Solution</title>
            <description>One intravitreous injection of 0,05 ml dexamethasone solution 4 mg/ml.
Intravitreous Dexamethasone Solution 4mg/ml - vol 0,05 ml: 0,05 ml intravitreous dexamethasone solution 4mg/ml injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Macular Thickness at 3 Days After Intravitreous Dexamethasone</title>
          <description>Measure macular thickness at 3 days after intravitreous dexamethasone with OCT - unit µm</description>
          <population>Macular thickness at 3 days after intravitreous dexamethasone</population>
          <units>µm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="438.44" spread="124.55"/>
                    <measurement group_id="O2" value="465.22" spread="115.25"/>
                    <measurement group_id="O3" value="368.22" spread="126.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Macular Thickness at 28 Days After Intravitreous Dexamethasone</title>
        <description>Measure macular thickness at 28 days after intravitreous dexamethasone with OCT - unit µm</description>
        <time_frame>28 days after intravitreous dexamethasone</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0,01ml Dexamethasone Solution</title>
            <description>One intravitreous injection of 0,01 ml dexamethasone solution 4 mg/ml.
Intravitreous Dexamethasone Solution 4mg/ml - vol 0,01 ml: 0,01 ml intravitreous dexamethasone solution 4mg/ml injection.</description>
          </group>
          <group group_id="O2">
            <title>0,03 ml Dexamethasone Solution</title>
            <description>One intravitreous injection of 0,03 ml dexamethasone solution 4 mg/ml.
Intravitreous Dexamethasone Solution 4mg/ml - vol 0,03 ml: 0,03 ml intravitreous dexamethasone solution 4mg/ml injection.</description>
          </group>
          <group group_id="O3">
            <title>0,05 ml Dexamethasone Solution</title>
            <description>One intravitreous injection of 0,05 ml dexamethasone solution 4 mg/ml.
Intravitreous Dexamethasone Solution 4mg/ml - vol 0,05 ml: 0,05 ml intravitreous dexamethasone solution 4mg/ml injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Macular Thickness at 28 Days After Intravitreous Dexamethasone</title>
          <description>Measure macular thickness at 28 days after intravitreous dexamethasone with OCT - unit µm</description>
          <units>µm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="554.66" spread="175.91"/>
                    <measurement group_id="O2" value="617.22" spread="245.83"/>
                    <measurement group_id="O3" value="451.44" spread="154.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Corrected Visual Acuity (BCVA) at 3 Days After Intravitreous Dexamethasone</title>
        <description>Measure best corrected visual acuity (BCVA) at 3 days after intravitreous dexamethasone with ETDRS chart</description>
        <time_frame>Three days after intravitreous dexamethasone</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0,01ml Dexamethasone Solution</title>
            <description>One intravitreous injection of 0,01 ml dexamethasone solution 4 mg/ml.
Intravitreous Dexamethasone Solution 4mg/ml - vol 0,01 ml: 0,01 ml intravitreous dexamethasone solution 4mg/ml injection.</description>
          </group>
          <group group_id="O2">
            <title>0,03 ml Dexamethasone Solution</title>
            <description>One intravitreous injection of 0,03 ml dexamethasone solution 4 mg/ml.
Intravitreous Dexamethasone Solution 4mg/ml - vol 0,03 ml: 0,03 ml intravitreous dexamethasone solution 4mg/ml injection.</description>
          </group>
          <group group_id="O3">
            <title>0,05 ml Dexamethasone Solution</title>
            <description>One intravitreous injection of 0,05 ml dexamethasone solution 4 mg/ml.
Intravitreous Dexamethasone Solution 4mg/ml - vol 0,05 ml: 0,05 ml intravitreous dexamethasone solution 4mg/ml injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Best Corrected Visual Acuity (BCVA) at 3 Days After Intravitreous Dexamethasone</title>
          <description>Measure best corrected visual acuity (BCVA) at 3 days after intravitreous dexamethasone with ETDRS chart</description>
          <units>ETDRS Letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.22" spread="12.77"/>
                    <measurement group_id="O2" value="52.33" spread="16.09"/>
                    <measurement group_id="O3" value="60.22" spread="17.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Corrected Visual Acuity (BCVA) at 28 Days After Intravitreous Dexamethasone</title>
        <description>Measure best corrected visual acuity (BCVA) at 28 days after intravitreous dexamethasone with ETDRS chart</description>
        <time_frame>28 days after intravitreous dexamethasone</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0,01ml Dexamethasone Solution</title>
            <description>One intravitreous injection of 0,01 ml dexamethasone solution 4 mg/ml.
Intravitreous Dexamethasone Solution 4mg/ml - vol 0,01 ml: 0,01 ml intravitreous dexamethasone solution 4mg/ml injection.</description>
          </group>
          <group group_id="O2">
            <title>0,03 ml Dexamethasone Solution</title>
            <description>One intravitreous injection of 0,03 ml dexamethasone solution 4 mg/ml.
Intravitreous Dexamethasone Solution 4mg/ml - vol 0,03 ml: 0,03 ml intravitreous dexamethasone solution 4mg/ml injection.</description>
          </group>
          <group group_id="O3">
            <title>0,05 ml Dexamethasone Solution</title>
            <description>One intravitreous injection of 0,05 ml dexamethasone solution 4 mg/ml.
Intravitreous Dexamethasone Solution 4mg/ml - vol 0,05 ml: 0,05 ml intravitreous dexamethasone solution 4mg/ml injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Best Corrected Visual Acuity (BCVA) at 28 Days After Intravitreous Dexamethasone</title>
          <description>Measure best corrected visual acuity (BCVA) at 28 days after intravitreous dexamethasone with ETDRS chart</description>
          <units>ETDRS letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.33" spread="15.46"/>
                    <measurement group_id="O2" value="50.55" spread="18.51"/>
                    <measurement group_id="O3" value="64.11" spread="16.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intraocular Pressure (IOP) at 3 Days After Intravitreous Dexamethasone</title>
        <description>Measure intraocular pressure (IOP) 3 days after intravitreous dexamethasone - unit mmHg</description>
        <time_frame>3 days after intravitreous dexamethasone</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0,01ml Dexamethasone Solution</title>
            <description>One intravitreous injection of 0,01 ml dexamethasone solution 4 mg/ml.
Intravitreous Dexamethasone Solution 4mg/ml - vol 0,01 ml: 0,01 ml intravitreous dexamethasone solution 4mg/ml injection.</description>
          </group>
          <group group_id="O2">
            <title>0,03 ml Dexamethasone Solution</title>
            <description>One intravitreous injection of 0,03 ml dexamethasone solution 4 mg/ml.
Intravitreous Dexamethasone Solution 4mg/ml - vol 0,03 ml: 0,03 ml intravitreous dexamethasone solution 4mg/ml injection.</description>
          </group>
          <group group_id="O3">
            <title>0,05 ml Dexamethasone Solution</title>
            <description>One intravitreous injection of 0,05 ml dexamethasone solution 4 mg/ml.
Intravitreous Dexamethasone Solution 4mg/ml - vol 0,05 ml: 0,05 ml intravitreous dexamethasone solution 4mg/ml injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Intraocular Pressure (IOP) at 3 Days After Intravitreous Dexamethasone</title>
          <description>Measure intraocular pressure (IOP) 3 days after intravitreous dexamethasone - unit mmHg</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.33" spread="3.90"/>
                    <measurement group_id="O2" value="13.11" spread="2.42"/>
                    <measurement group_id="O3" value="12.44" spread="3.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intraocular Pressure (IOP) at 28 Days After Intravitreous Dexamethasone</title>
        <description>Measure intraocular pressure (IOP) 28 days intravitreous dexamethasone - unit mmHg</description>
        <time_frame>28 days after intravitreous dexamethasone</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0,01ml Dexamethasone Solution</title>
            <description>One intravitreous injection of 0,01 ml dexamethasone solution 4 mg/ml.
Intravitreous Dexamethasone Solution 4mg/ml - vol 0,01 ml: 0,01 ml intravitreous dexamethasone solution 4mg/ml injection.</description>
          </group>
          <group group_id="O2">
            <title>0,03 ml Dexamethasone Solution</title>
            <description>One intravitreous injection of 0,03 ml dexamethasone solution 4 mg/ml.
Intravitreous Dexamethasone Solution 4mg/ml - vol 0,03 ml: 0,03 ml intravitreous dexamethasone solution 4mg/ml injection.</description>
          </group>
          <group group_id="O3">
            <title>0,05 ml Dexamethasone Solution</title>
            <description>One intravitreous injection of 0,05 ml dexamethasone solution 4 mg/ml.
Intravitreous Dexamethasone Solution 4mg/ml - vol 0,05 ml: 0,05 ml intravitreous dexamethasone solution 4mg/ml injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Intraocular Pressure (IOP) at 28 Days After Intravitreous Dexamethasone</title>
          <description>Measure intraocular pressure (IOP) 28 days intravitreous dexamethasone - unit mmHg</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.33" spread="3.16"/>
                    <measurement group_id="O2" value="12.44" spread="2.74"/>
                    <measurement group_id="O3" value="11.88" spread="2.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected during the study period - 28 days.</time_frame>
      <desc>Dexamethasone solution 4mg/ml used in the study does not have impact in cardiovascular events.</desc>
      <group_list>
        <group group_id="E1">
          <title>0,01ml Dexamethasone Solution</title>
          <description>One intravitreous injection of 0,01 ml dexamethasone solution 4 mg/ml.
Intravitreous Dexamethasone Solution 4mg/ml - vol 0,01 ml: 0,01 ml intravitreous dexamethasone solution 4mg/ml injection.</description>
        </group>
        <group group_id="E2">
          <title>0,03 ml Dexamethasone Solution</title>
          <description>One intravitreous injection of 0,03 ml dexamethasone solution 4 mg/ml.
Intravitreous Dexamethasone Solution 4mg/ml - vol 0,03 ml: 0,03 ml intravitreous dexamethasone solution 4mg/ml injection.</description>
        </group>
        <group group_id="E3">
          <title>0,05 ml Dexamethasone Solution</title>
          <description>One intravitreous injection of 0,05 ml dexamethasone solution 4 mg/ml.
Intravitreous Dexamethasone Solution 4mg/ml - vol 0,05 ml: 0,05 ml intravitreous dexamethasone solution 4mg/ml injection.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <description>Incidence of endophthalmitis after intravitreous dexamethasone solution</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <description>Incidence of retinal detachment after intravitreous dexamethasone solution</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Intraocular pressure elevation (IOP) &gt; 5 mmHg from baseline</sub_title>
                <description>Intraocular pressure elevation &gt; 5 mmHg from baseline or that required anti hypertensive ocular medication</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The primary limitation of this study was the small number of participants, likely due to the strict inclusion criteria selected.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Rodrigo Pessoa Cavalcanti Lira</name_or_title>
      <organization>State University of Campinas (UNICAMP)</organization>
      <phone>551935217396 ext 7396</phone>
      <email>alayf@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

